TABLE 2.
The association between subtypes and clinicopathologic variables of prostate cancer.
| clinicopathologic variables | Subtype | P | ||
|---|---|---|---|---|
| Risk_L (n = 51) | Risk_M (n = 199) | Risk_H (n = 234) | ||
| Age (year), median (IQR) | 61.0 (56.0–67.5) | 61.0 (56.0–66.0) | 62.0 (57.0–66.0) | 0.307a |
| PSA (ng/ml), median (IQR) | 6.1 (4.2–10.0) | 7.2 (5.0–10.8) | 7.8 (5.2–12.8) | 0.017a |
| Pathological Gleason score, n (%) | < 0.001b | |||
| ≤6 | 8 (15.7%) | 16 (8.0%) | 19 (8.1%) | |
| 7 (3+4) | 18 (35.3%) | 75 (37.7%) | 49 (20.9%) | |
| 7 (4+3) | 10 (19.6%) | 44 (22.1%) | 47 (20.1%) | |
| 8 | 3 (5.9%) | 28 (14.1%) | 30 (12.8%) | |
| 9–10 | 12 (23.5%) | 36 (18.1%) | 89 (38.0%) | |
| Prior malignancy, n (%) | 0.562c | |||
| No | 50 (98.0%) | 187 (94.0%) | 219 (93.6%) | |
| Yes | 1 (2.0%) | 12 (6.0%) | 15 (6.4%) | |
| Race, n (%) | 0.804c | |||
| Asian | 1 (2.0%) | 3 (1.5%) | 8 (3.4%) | |
| Whit, American Indian or Alaska native | 43 (84.3%) | 169 (84.9%) | 192 (82.1%) | |
| Black or African American | 5 (9.9%) | 22 (11.1%) | 27 (11.5%) | |
| NA | 2 (3.8%) | 5 (2.5%) | 7 (3.0%) | |
| Residual tumor, n (%) | ||||
| R0 | 31 (60.8%) | 138 (69.3%) | 139 (59.4%) | 0.035b |
| Rx/R1/R2 | 19 (37.3%) | 53 (26.6%) | 91 (38.9%) | |
| NA | 1 (1.9%) | 8 (4.1%) | 4 (1.7%) | |
| Clinical M, n (%) | 1.000c | |||
| M0 | 49 (96.1%) | 182 (91.5%) | 213 (91.0%) | |
| M1a or M1c | 0 (0.0%) | 1 (0.5%) | 1 (0.4%) | |
| NA | 2 (3.9%) | 16 (8.0%) | 20 (8.6%) | |
| Pathological T, n (%) | 0.027c | |||
| T1c | 0 (0.0%) | 2 (1.0%) | 0 (0.0%) | |
| T2a | 2 (3.9%) | 4 (2.0%) | 7 (3.0%) | |
| T2b | 2 (3.9%) | 3 (1.5%) | 5 (2.1%) | |
| T2c | 18 (35.3%) | 84 (42.2%) | 59 (25.2%) | |
| T3a | 16 (31.4%) | 60 (30.2%) | 81 (34.6%) | |
| T3b | 12 (23.5%) | 63 (21.6%) | 75 (32.1%) | |
| T4 | 1 (2.0%) | 2 (1.0%) | 6 (2.6%) | |
| NA | 0 (0.0%) | 1 (0.5%) | 1 (0.4%) | |
| Pathological N, n (%) | 0.141b | |||
| N0 | 31 (60.8%) | 149 (74.9%) | 155 (66.2%) | |
| N1 | 7 (13.7%) | 26 (13.1%) | 46 (19.7%) | |
| NA | 13 (25.5%) | 24 (12.0%) | 33 (14.1%) | |
| Outcome, n (%) | ||||
| DFS | 1 (2.0%) | 15 (7.5%) | 41 (17.5%) | <0.001b |
| Disease free | 50 (98.0%) | 184 (92.5%) | 193 (82.5.0%) | |
p values were calculated by the Kruskal test (a), Chi-square test (b) or Fisher’s exact test (c). DFS, Disease-free survival; IQR, interquartile range; NA, not analyzed; PCa, prostate cancer; PSA, Prostate-specific antigen.